Centrifugation: When plasma is required, or when not using a serum gel separator tube, follow these instructions: 1  Draw 12 mL of whole blood for each 5 mL of serum or plasma needed. 2  Centrifuge for at least 15 minutes at 2200-2500 RPM. 3  Pipette the serum or plasma into a clean plastic screw-cap vial and attach the label.
Buccal administration; Naloxone; Naltrexone; opioid antagonist; Pharmacokinetics; First-pass metabolism Summary The opioid antagonists naloxone and naltrexone are both known to undergo extensive first-pass metabolism after oral dosing. The buccal route was investigated as a potential alternative to oral administration. Oral and buccal bioavailabilities of naloxone and naltrexone were determined in rats. Less than 1 % of oral naloxone or naltrexone was bioavailable, but buccal administration resulted in approximately 70% bioavailability for each drug.
Naltrexone is a medication used in medication-assisted treatment (MAT) to treat both opioid and alcohol use disorders. Naltrexone is a medication approved by the Food and Drug Administration (FDA) to treat opioid use disorders and alcohol use disorders. It comes in a pill form or as an injectable. The pill form of naltrexone (ReVia, Depade) can be taken at 50 mg once per day. The injectable extended-release form of the drug (Vivitrol) is administered at 380 mg intramuscular once a month. Naltrexone can be prescribed by any health care provider who is licensed to prescribe medications. To reduce the risk of precipitated withdrawal, patients are warned to abstain from illegal opioids and opioid medication for a minimum of 7-10 days before starting naltrexone.